Literature DB >> 26131290

Is dabigatran efficacy enough to prevent stroke in atrial fibrillation patient with high CHADS2 score during peri-procedural catheter radiofrequency ablation? A case report with literature review.

Xiang-Min Shi1, Fu-Kun Chen1, Zhuo Liang1, Jian Li1, Kun Lin1, Jian-Ping Guo1, Zhao-Liang Shan1.   

Abstract

Atrial fibrillation (AF) is a major cause of thromboembolic (TE) events including stroke and transient ischemic attacks, catheter radiofrequency ablation (CA) has been demonstrated to effectively eliminate AF in majority of patients. During the peri-procedural CA of AF, dabigatran, a reversible direct thrombin inhibitor, has been proved as safe and efficacy as warfarin in the prevention of thromboembolic complication. However, for patients with CHADS2 score ≥3, sometimes dabigatran may not be an ideal substitute of warfarin. The current study presents delayed stroke occurred in a middle-aged AF patient with high CHADS2 score who had undergone successful CA of AF being on dabigatran, trans esophageal echocardiogram (TEE) detected a clot in the left atrium appendage (LAA) and magnetic resonance image (MRI) indicated stroke of left basal ganglia, therefore anticoagulant was switched to warfarin with well controlled international normalization ratio (INR) ranging from 2.0-3.0 and the patient eventually recovered without any TE events during the subsequent follow-up.

Entities:  

Keywords:  Atrial fibrillation; catheter radiofrequency ablation; dabigatran; left atrium appendage; thromboembolic events

Year:  2015        PMID: 26131290      PMCID: PMC4483948     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  45 in total

Review 1.  Dabigatran etexilate: a new oral thrombin inhibitor.

Authors:  Graeme J Hankey; John W Eikelboom
Journal:  Circulation       Date:  2011-04-05       Impact factor: 29.690

Review 2.  Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

Authors:  Aref A Bin Abdulhak; Abdur Rahman Khan; Imad M Tleyjeh; John A Spertus; Susan U Sanders; Kristy E Steigerwalt; Musa A Garbati; Reem A Bahmaid; Alan P Wimmer
Journal:  Europace       Date:  2013-08-16       Impact factor: 5.214

3.  Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation.

Authors:  Jonathan P Piccini; Moritz F Sinner; Melissa A Greiner; Bradley G Hammill; João D Fontes; James P Daubert; Patrick T Ellinor; Adrian F Hernandez; Allan J Walkey; Susan R Heckbert; Emelia J Benjamin; Lesley H Curtis
Journal:  Circulation       Date:  2012-09-26       Impact factor: 29.690

4.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

5.  Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy.

Authors:  Ayman A Hussein; David O Martin; Walid Saliba; Deven Patel; Saima Karim; Omar Batal; Mustafa Banna; Michelle Williams-Andrews; Minerva Sherman; Mohamed Kanj; Mandeep Bhargava; Thomas Dresing; Thomas Callahan; Patrick Tchou; Luigi Di Biase; Salwa Beheiry; Bruce Lindsay; Andrea Natale; Oussama Wazni
Journal:  Heart Rhythm       Date:  2009-07-10       Impact factor: 6.343

6.  Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation.

Authors:  Daniel Scherr; Kavita Sharma; Darshan Dalal; David Spragg; Karuna Chilukuri; Alan Cheng; Jun Dong; Charles A Henrikson; Saman Nazarian; Ronald D Berger; Hugh Calkins; Joseph E Marine
Journal:  J Cardiovasc Electrophysiol       Date:  2009-12

7.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Trans-septal catheterization in the electrophysiology laboratory: data from a multicenter survey spanning 12 years.

Authors:  Roberto De Ponti; Riccardo Cappato; Antonio Curnis; Paolo Della Bella; Luigi Padeletti; Antonio Raviele; Massimo Santini; Jorge A Salerno-Uriarte
Journal:  J Am Coll Cardiol       Date:  2006-02-09       Impact factor: 24.094

9.  Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.

Authors:  Mohamed Bassiouny; Walid Saliba; John Rickard; Mingyuan Shao; Albert Sey; Mariam Diab; David O Martin; Ayman Hussein; Maurice Khoury; Bernard Abi-Saleh; Samir Alam; Jay Sengupta; P Peter Borek; Bryan Baranowski; Mark Niebauer; Thomas Callahan; Niraj Varma; Mina Chung; Patrick J Tchou; Mohamed Kanj; Thomas Dresing; Bruce D Lindsay; Oussama Wazni
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-04-03

10.  Prevalence of atrial fibrillation in patients with high CHADS2- and CHA2DS2VASc-scores: anticoagulate or monitor high-risk patients?

Authors:  Tina s Tischer; Ralph Schneider; Jörg Lauschke; Catharina Nesselmann; Anke Klemm; Doreen Diedrich; Günther Kundt; Dietmar Bänsch
Journal:  Pacing Clin Electrophysiol       Date:  2014-12       Impact factor: 1.976

View more
  1 in total

1.  Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease.

Authors:  Yong-Ming Zhou; Ming-Jiang Li; Yan-Li Zhou; Le-Le Ma; Xin Yi
Journal:  Int J Clin Exp Med       Date:  2015-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.